What is PT-141?

PT-141 is a research peptide in the Body Recomposition class. MC4-receptor agonist; investigated for sexual function. It is studied at per-dose ranges of 1–1.75 mg PRN (As needed weekly), administered prn sc over cycles of prn. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

7-amino-acid melanocortin agonist (bremelanotide). FDA-approved for HSDD in premenopausal women.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does PT-141 work?

Primary mechanism: MC4-receptor agonist; investigated for sexual function. Research on PT-141 implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for PT-141 remain areas of active investigation; several proposed effects within the Body Recomposition class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

PT-141 dosage & protocol

Reference protocol for PT-141 (research context only, drawn from published literature):

  • Per dose: 1–1.75 mg PRN
  • Weekly total: As needed
  • Frequency: PRN SC
  • Cycle: PRN

Stacking PT-141

Commonly referenced pairing with PT-141: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a PT-141 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Uncontrolled hypertension. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

PT-141 — common questions

What is PT-141 and what is it used for in research?
PT-141 is classified within the Body Recomposition group. 7-amino-acid melanocortin agonist (bremelanotide). FDA-approved for HSDD in premenopausal women. Research applications focus on the pathways outlined below. All references on this page describe published research only — PT-141 is supplied for in-vitro and laboratory use, not for human consumption.
How does PT-141 work?
Primary mechanism: MC4-receptor agonist; investigated for sexual function. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for PT-141 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical PT-141 research dose?
Published research protocols for PT-141 describe per-dose ranges of 1–1.75 mg PRN, with a weekly total near As needed, administered prn sc. Typical cycle: prn. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy PT-141 in Thailand?
PT-141 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can PT-141 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019. PMID: 31599840

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.